ECE2016 18th European Congress of Endocrinology 2016 The Geoffrey Harris Prize Lecture (2 abstracts)
The European Society of Endocrinology is pleased to present the annual Geoffrey Harris Prize. This prestigious prize is designed for established researchers in the field of neuroendocrinology and is the first of its kind in Europe. The prize will be presented at the annual European Congress of Endocrinology, where the winner will be asked to give one of the main lectures, in addition to two other lectures at future ESE scientific meetings.
Dr Albert Beckers MD, PhD, is Chief of the Department of Endocrinology at the University Hospital Centre, Liège and Full Professor at the University of Liège, Belgium. After completing his medical degree at the University of Louvain, Belgium, Prof. Beckers undertook specialty training in Endocrinology, Internal Medicine and Nuclear Medicine. He oversees a Department with multiple clinical and research areas of interest, including pituitary tumors, thyroid disease, genetic causes of endocrine cancers and rare inherited syndromes. Prof. Beckers has taken a particular interest in endocrine education, authoring a highly regarded series of digital projects on aspects of pituitary disease. He has published more than 250 original articles in journals such as the New England Journal of Medicine, Endocrine Reviews, and the Journal of Clinical Endocrinology & Metabolism. Research highlights include the original characterization and description of the syndrome, Familial Isolated Pituitary Adenomas (FIPA) and a newly described pediatric syndrome X-Linked Acrogigantism (X-LAG).
Prof. Beckers has served two mandates as President of the Belgian Endocrine Society, has been the Secretary of the European NeuroEndocrine Association (ENEA), and has organised many national and international Congresses. Current research interests include the genetics of pituitary diseases, molecular and genetic investigation of rare disorders of endocrine development, gigantism and acromegaly and the study of new treatment options for aggressive endocrine tumors.